+

WO1992018111A3 - Pharmaceutical composition for the treatment of gastritis - Google Patents

Pharmaceutical composition for the treatment of gastritis Download PDF

Info

Publication number
WO1992018111A3
WO1992018111A3 PCT/GB1992/000551 GB9200551W WO9218111A3 WO 1992018111 A3 WO1992018111 A3 WO 1992018111A3 GB 9200551 W GB9200551 W GB 9200551W WO 9218111 A3 WO9218111 A3 WO 9218111A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pharmaceutical composition
gastritis
administered
release
Prior art date
Application number
PCT/GB1992/000551
Other languages
French (fr)
Other versions
WO1992018111A2 (en
Inventor
Philip Lea
Mark Coke
Kim Morwood
Andrew William Smith
Original Assignee
Smith Kline Beecham Plc
Philip Lea
Mark Coke
Kim Morwood
Andrew William Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Beecham Plc, Philip Lea, Mark Coke, Kim Morwood, Andrew William Smith filed Critical Smith Kline Beecham Plc
Priority to JP4506927A priority Critical patent/JPH06506919A/en
Publication of WO1992018111A2 publication Critical patent/WO1992018111A2/en
Publication of WO1992018111A3 publication Critical patent/WO1992018111A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A pharmaceutical composition for use in the treatment of gastric disorders associated with Helicobacter pylori comprising an antimicrobial agent optionally co-administered with a release-delaying substance.
PCT/GB1992/000551 1991-04-15 1992-03-25 Pharmaceutical composition for the treatment of gastritis WO1992018111A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4506927A JPH06506919A (en) 1991-04-15 1992-03-25 Pharmaceutical composition for gastritis treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9108080.4 1991-04-15
GB919108080A GB9108080D0 (en) 1991-04-15 1991-04-15 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
WO1992018111A2 WO1992018111A2 (en) 1992-10-29
WO1992018111A3 true WO1992018111A3 (en) 1992-12-10

Family

ID=10693364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/000551 WO1992018111A2 (en) 1991-04-15 1992-03-25 Pharmaceutical composition for the treatment of gastritis

Country Status (5)

Country Link
EP (1) EP0580627A1 (en)
JP (1) JPH06506919A (en)
AU (1) AU1430492A (en)
GB (1) GB9108080D0 (en)
WO (1) WO1992018111A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
EP0713392A1 (en) * 1994-05-11 1996-05-29 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including h. pylori, infections and related diseases
US5660842A (en) * 1994-10-04 1997-08-26 Bristol-Myers Squibb Company Inhibition of helicobacter
US5804549A (en) * 1996-01-05 1998-09-08 Ambi Inc. Compositions with activity against helicobacter
ZA9610949B (en) * 1996-01-05 1997-08-14 Applied Microbiology Inc Monoglyceride compositions and their use against Helicobacter.
JPH09328404A (en) * 1996-06-07 1997-12-22 Iwao Hishida Microbicidal, antimicrobial and inactivating agent
JP2000516606A (en) * 1996-08-13 2000-12-12 ピー・エヌ・ゲロリマトス・ソシエテ・アノニム Use of the chelating agent clioquinol in the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
DK0988033T3 (en) * 1997-01-09 2001-10-22 Bifodan As Use of dichlorobenzyl alcohol to prepare a composition for topical treatment of inflammation
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US5980914A (en) * 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6881731B1 (en) * 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
WO2003017964A1 (en) 2001-08-24 2003-03-06 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
WO2003017963A1 (en) * 2001-08-24 2003-03-06 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
JP2016000709A (en) * 2014-06-12 2016-01-07 仲邑 羅 Method for inhibiting helicobacter pylori
CN116747165A (en) * 2023-05-22 2023-09-15 西埔(福建)医药用品有限公司 Mouthwash capable of killing helicobacter pylori in mouth and having antibacterial and deodorant effects

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR677M (en) * 1960-09-22 1961-07-17
FR2559M (en) * 1962-05-02 1964-06-01 Pharmacotechnique Dubois & Vin
FR3623M (en) * 1964-05-13 1965-10-18 Rhone Poulenc Sa New dibromopropamidine salts and compositions containing them.
EP0078599A2 (en) * 1981-09-01 1983-05-11 Teikoku Chemical Industry Co., Ltd. Complex compounds based on cyclodextrins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR677M (en) * 1960-09-22 1961-07-17
FR2559M (en) * 1962-05-02 1964-06-01 Pharmacotechnique Dubois & Vin
FR3623M (en) * 1964-05-13 1965-10-18 Rhone Poulenc Sa New dibromopropamidine salts and compositions containing them.
EP0078599A2 (en) * 1981-09-01 1983-05-11 Teikoku Chemical Industry Co., Ltd. Complex compounds based on cyclodextrins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Acta Gastro-enterologica Belgica, vol. 51, nos. 4-5, July-October 1988, Y. Glupczynski et al.: "Campylobacter pylori-associated gastritis: attempts to eradicate the bacteria by various antibiotics and anti-ulcer regimens", pages 329-337, see page 333 *
Journal of Pharmaceutical Sciences, vol. 73, no. 1, January 1984, Am. Pharm. Association, US; G.W. Schieffer et al.: "Simultaneous determination of methyl, ethyl, propyl, and butyl 4-hydroxybenzoates and 4-hydroxybenzoic acid in liquid antacid formulations by gas chromatography", pages 128-131, see page 128 *
R. Dolder & F.S. Skinner: Ophthalmika, 3rd Edition, 1983, Wissenschafliche Verlagsgesellschaft mbH, Stuttgart, DE; pages 92-94, see page 93 *
Scand. J. Gastroenterol, Suppl. vol. 155, 1988, G.N.J. Tytgat et al.: "Campylobacter pylori", pages 68-81, see page 73 *
Schweizerische Medizinische Wochenschrift, vol. 118, no. 16, 23rd April 1988, Schwabe & Cie. SA, Bâle, CH; J.-O. Gebbers et al.: "Campylobacter pylori: Ursache von Gastritis und Ulkuskrankheit?, pages 577-583, see page 581 *

Also Published As

Publication number Publication date
WO1992018111A2 (en) 1992-10-29
JPH06506919A (en) 1994-08-04
AU1430492A (en) 1992-11-17
GB9108080D0 (en) 1991-06-05
EP0580627A1 (en) 1994-02-02

Similar Documents

Publication Publication Date Title
CA2108455A1 (en) Pharmaceutical compositions against gastric disorders
WO1992018111A3 (en) Pharmaceutical composition for the treatment of gastritis
PH31205A (en) Pharmaceutical composition.
ZA926019B (en) Pharmaceutical spheroid formulation.
IE862554L (en) Pharmaceutical compositions
AU6517496A (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
EP2329829A3 (en) Use of uridine in combination with choline for the treatment of memory disorders
EP0640097A4 (en) Compositions and methods for vaccination against coronaviruses.
GB2259647B (en) Medicaments for treating gastrointestinal disorders
AU7472191A (en) Therapeutic composition containing a phenol compound and propolis useful against lipidic capside viruses, especially the herpes viruses
PH31073A (en) Pharmaceutical composition and process for the preparation thereof.
AU4517893A (en) An oral formulation for gastric antibacterial treatment as well as a process thereof and the use
OA09810A (en) Pharmaceutical composition.
AU638083B2 (en) Swallowable dosage units comprising colloidal bismuth subcitrate
WO1998010762A3 (en) Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
AU1247292A (en) Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
CY2167B1 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinylue benzimidazole and an anti-helicobacter agent f or the treatment of gastrointestinal disorders
AU4734993A (en) Nutrient or medicinal compositions for administration to ruminants
IL109866A (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)L-hydrogentartrate its preparation and pharmaceutical compositions containing it
CS240991A3 (en) Solid forms for oral administration, said forms containing iphosphamide as active component
IL81549A0 (en) Pharmaceutical compositions containing glycerophosphoryl-o-serine or a salt thereof,certain such novel salts and their preparation
AU8614291A (en) Device for administering drugs
AU5894494A (en) The use of a composition for the treatment of infections caused by helicobacter pylori
IT1244360B (en) Zinc hydroxide preparation for the treatment of gastric and duodenal ulcers in man.
ZA928359B (en) Controlled release pharmaceutical compositions.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992907325

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1993 133030

Date of ref document: 19931008

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1992907325

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1992907325

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载